Novo's obesity drug will cost U.S. patients over $1,000 per month

• Novo Nordisk (NVO -0.4%) launches its obesity drug Saxenda (liraglutide) today in the U.S. According to Reuters, it will cost $1,068 per month. Out-of-pocket costs for patients will depend, of course, on their insurance coverage.
• The FDA approved Saxenda in late December.
• Previously: FDA clears Novo weight management drug (Dec. 23, 2014)
• Related tickers: (OREX -2.5%)(VVUS +0.2%)(ARNA +1.1%)